Abbott Laboratories (ABT)vsAnheuser Busch Inbev NV ADR (BUD)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
BUD
Anheuser Busch Inbev NV ADR
$68.06
-0.71%
CONSUMER DEFENSIVE · Cap: $133.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 34% more annual revenue ($59.32B vs $44.33B). ABT leads profitability with a 14.7% profit margin vs 11.5%. ABT appears more attractively valued with a PEG of 1.52. BUD earns a higher WallStSmart Score of 61/100 (C+).
ABT
Buy51
out of 100
Grade: C-
BUD
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
+51.3%
Fair Value
$158.65
Current Price
$68.06
$90.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Earnings expanding 63.3% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 24.9%
Generating 9.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Expensive relative to growth rate
4.8% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : BUD
The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ABT carries more volatility with a beta of 0.74 — expect wider price swings.
BUD is growing revenue faster at 4.8% — sustainability is the question.
BUD generates stronger free cash flow (9.9B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BUD scores higher overall (61/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?